Immunitas Therapeutics

Immunitas is unlocking human immunology using novel single cell analyses to develop targeted therapeutics for patients with challenging, complex cancers. Translating findings from laboratory research to meaningful clinical advances in humans is a longstanding challenge in the oncology field. Immunitas was founded to directly address this problem and unlock a variety of novel drug targets based on discovery rooted in human biology. They are pursuing this goal with a team of pioneers in these areas across their scientific founders, management, and investors.

At Immunitas, they employ a single cell sequencing platform to dissect the biology of immune cells in human tumors. Their focus on human samples allows us to start with and stay closer to the most relevant and translatable biology for patients and accelerates the pace of their research. They are identifying novel, exciting oncology targets and, importantly, developing key biomarkers to guide the selection of patients who may benefit from their new drugs. They are leveraging expertise in antibody discovery and engineering to create powerful therapies that modulate these targets, and are currently advancing a number of programs toward early human studies.

Immunitas Therapeutics headquartered in United States, North America, operates in the Biotechnology, Life Science, Health Care, Therapeutics, Oncology sector. The company focuses on Biotechnology and has secured $3.9B in funding across 40 round(s). With a team of 11-50 employees, Immunitas Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Immunitas Therapeutics, raised $58.0M. Discover more about their projects, partnerships, and impact on our platform.